Herbal Monograph
Milk thistle
Silybum marianum (L.) Gaertn.
Asteraceae (Compositae)
Premier hepatoprotective herb for liver health, protection, and regeneration
Overview
Plant Description
Milk thistle is an annual or biennial herbaceous plant growing 30-200 cm (1-6.5 feet) tall with a stout, erect, branching stem that is grooved and somewhat cottony. Basal leaves are large (up to 50 cm long, 25 cm wide), oblong-lanceolate, deeply lobed with spiny-toothed margins, glossy dark green with conspicuous white marbling along the veins -- the most distinctive identifying feature. Upper leaves are smaller, clasping the stem. The white venation pattern was attributed in Christian legend to drops of the Virgin Mary's milk, giving rise to the common names 'milk thistle' and 'St. Mary's thistle.' Flower heads are large (4-5 cm diameter), solitary, terminal, with purple-red tubular disc florets surrounded by stiff, spreading, spine-tipped bracts. The fruit is a hard-shelled achene (cypsela), 6-7 mm long, dark brown to black with a pale pappus of simple hairs. The seeds (technically achenes) are the medicinal part and contain the pharmacologically active silymarin complex concentrated in the seed coat (pericarp).
Habitat
Native to the Mediterranean region, preferring dry, sunny habitats. Thrives in well-drained, stony or sandy soils in full sun. Commonly found in waste ground, roadsides, pastures, field margins, and disturbed areas. Tolerates poor soil and moderate drought. Prefers neutral to slightly alkaline soil pH (6.5-8.0). Classified as a noxious weed in some regions (Australia, parts of North and South America) due to its aggressive colonization of disturbed land.
Distribution
Native to the Mediterranean basin, southern Europe, North Africa, and the Middle East. Widely naturalized throughout central and western Europe, the Americas (North, Central, and South), southern Australia, and parts of Asia. Major commercial cultivation in Germany, Austria, Hungary, Poland, China, Argentina, Venezuela, and Egypt. Germany, Poland, and China are among the largest producers for the pharmaceutical market.
Parts Used
Seed / Fruit (achenes) -- Silybi mariani fructus
Preferred: Standardized extract (70-80% silymarin); capsule of ground seed; tincture of crushed seeds
The ripe seeds (technically achenes, a dry single-seeded fruit) are the official drug in all major pharmacopeias and regulatory monographs (Ph. Eur., WHO, Commission E, ESCOP, EMA). The silymarin complex is concentrated in the seed coat (pericarp) at 1.5-3% w/w. European Pharmacopoeia requires minimum 1.5% silymarin calculated as silibinin (HPLC). Both whole crushed seeds and standardized extracts are used therapeutically. The whole plant (leaves, roots) has been used historically as a food, but only the seeds are recognized as the medicinal part.
Key Constituents
Flavonolignans (the silymarin complex)
The silymarin complex (total flavonolignans, 1.5-3% of seed weight) is responsible for the primary hepatoprotective, antioxidant, and anti-inflammatory actions of milk thistle. Silymarin's hepatoprotective mechanisms include: (1) antioxidant free radical scavenging and inhibition of lipid peroxidation; (2) cell membrane stabilization by incorporating into the outer hepatocyte membrane, reducing toxin permeability; (3) stimulation of ribosomal RNA polymerase I, promoting hepatocyte protein synthesis and regeneration; (4) anti-fibrotic activity via inhibition of hepatic stellate cell activation and reduction of collagen deposition; (5) anti-inflammatory activity through NF-kB suppression and inhibition of pro-inflammatory cytokine release. Standardized extracts are typically concentrated to 70-80% total silymarin (calculated as silibinin). Bioavailability of native silymarin is limited (20-50% oral absorption) due to poor water solubility; phospholipid complexes (phytosomes) and micronized formulations significantly improve absorption.
Flavonoids
Taxifolin is the most therapeutically relevant flavonoid in milk thistle seed, serving both as a direct antioxidant and as the biosynthetic precursor to all silymarin flavonolignans. The trace flavonoids (quercetin, kaempferol, apigenin) contribute modestly to the total antioxidant capacity.
Fixed (fatty) oil
The seed contains 20-30% fixed oil, rich in essential fatty acids (particularly linoleic acid). The oil contributes to the nutritional profile and serves as a matrix for the lipophilic flavonolignans. Cold-pressed milk thistle seed oil is used as a culinary oil in some traditions. The lipid content is relevant to extraction and formulation of silymarin preparations.
Other constituents
These secondary constituents complement the primary silymarin activity. Betaine provides additional hepatoprotective and lipotropic support. The protein content contributes to the nutritive aspects of whole seed preparations. Phytosterols may contribute modestly to cholesterol metabolism effects observed in some studies.
Herbal Actions
Protects the liver from damage
The defining pharmacological action of milk thistle. Silymarin protects hepatocytes through multiple synergistic mechanisms: (1) potent antioxidant activity -- scavenging free radicals and inhibiting lipid peroxidation, thereby protecting hepatocyte membranes from oxidative damage; (2) membrane stabilization -- silibinin incorporates into the outer lipid layer of hepatocyte membranes, reducing permeability to toxins; (3) stimulation of hepatocyte regeneration -- silibinin activates RNA polymerase I in the nucleus, increasing ribosomal protein synthesis and promoting liver cell regeneration; (4) anti-fibrotic activity -- inhibits hepatic stellate cell activation and collagen deposition, reducing progression of fibrosis; (5) anti-inflammatory action -- suppresses NF-kB-mediated inflammatory pathways and reduces pro-inflammatory cytokine production. Commission E approved for supportive treatment of chronic inflammatory liver conditions and hepatic cirrhosis. IV silibinin (Legalon SIL) is used as an antidote in Amanita phalloides mushroom poisoning in Europe, where it blocks hepatocellular toxin uptake by competing for transmembrane transport proteins.
[1, 2, 7, 18, 19]Prevents or slows oxidative damage to cells
Silymarin is a potent antioxidant operating through both direct and indirect mechanisms. Direct: scavenges reactive oxygen species (ROS) including superoxide anion, hydroxyl radical, and hydrogen peroxide. Inhibits lipid peroxidation in hepatocyte membranes. Indirect: maintains and restores intracellular glutathione (GSH) levels -- the liver's primary endogenous antioxidant. Silymarin increases GSH by up to 35% in liver tissue in animal studies. Also induces superoxide dismutase (SOD) activity in erythrocytes and lymphocytes. The antioxidant activity is fundamental to the hepatoprotective mechanism, as oxidative stress is a central pathway in most forms of liver injury.
[18, 19, 20]Stimulates bile flow from the gallbladder
Silymarin stimulates bile flow (choleretic effect) and improves bile composition. Commission E approved for dyspeptic complaints, which includes bile-related digestive disturbance. The cholagogue action supports fat digestion and hepatobiliary clearance. Historically, the bitter taste of milk thistle seed preparations also contributes to reflexive stimulation of biliary secretion via the bitter taste receptor-vagal nerve pathway.
[1, 2, 6]Reduces inflammation
Silymarin suppresses NF-kB activation, a master regulator of inflammatory gene expression. Inhibits production of pro-inflammatory cytokines including TNF-alpha, IL-1beta, and IL-6. Reduces COX-2 expression and prostaglandin synthesis. Inhibits neutrophil migration and leukotriene formation. The anti-inflammatory action is particularly relevant to the hepatoprotective indication, where chronic hepatic inflammation drives fibrosis and cirrhosis progression. Also demonstrated in non-hepatic inflammatory models.
[18, 19, 20]Promotes breast milk production
Traditional use as a galactagogue (promoter of breast milk production) dating back centuries. The common name 'milk thistle' and white leaf veining were associated with lactation support in the Doctrine of Signatures tradition. A small RCT by Di Pierro et al. (2008) found that a micronized silymarin preparation (BIO-C, 420 mg/day) significantly increased daily milk production by 85.9% compared to 32.1% with placebo in lactating women. The mechanism is not well characterized but may involve dopaminergic modulation or prolactin-related effects. Evidence remains limited.
[6, 11, 16]Stimulates digestive secretions via bitter taste receptors
The ground seeds possess a distinctly bitter taste that stimulates digestive secretions, including gastric acid, bile, and pancreatic enzymes, via the bitter taste receptor-vagal nerve reflex. Commission E approved milk thistle for dyspeptic complaints, an indication consistent with its bitter tonic properties. The bitter quality is complementary to the cholagogue action.
[1, 6]Soothes and protects irritated mucous membranes
Minor demulcent activity from the mucilage content of whole seeds. Relevant primarily when ground seed is used rather than standardized extract. Provides mild soothing of GI mucosal surfaces.
[6]Therapeutic Indications
Hepatobiliary System
Chronic inflammatory liver disease (chronic hepatitis, alcoholic liver disease)
Commission E approved indication: supportive treatment for chronic inflammatory liver conditions. Ferenci et al. (1989) landmark double-blind, placebo-controlled trial in 170 patients with cirrhosis found significantly improved 4-year survival in the silymarin group (58%) vs placebo (39%) (P = 0.036), with the most pronounced benefit in alcoholic cirrhosis subgroup. Saller et al. (2001) systematic review confirmed hepatoprotective effects in chronic liver disease. Flora et al. (1998) review in the American Journal of Gastroenterology provided a comprehensive clinical overview. WHO monograph supports use for toxic, metabolic, and inflammatory liver damage. The EMA assessment report acknowledges well-established use for liver complaints.
[1, 2, 3, 7, 18, 22]Hepatic cirrhosis (supportive treatment)
Commission E approved for supportive treatment of hepatic cirrhosis. Multiple clinical trials have evaluated silymarin in cirrhosis with mixed results. Ferenci et al. (1989) showed survival benefit, particularly in alcoholic cirrhosis. However, the Rambaldi et al. (2007) Cochrane systematic review of 18 RCTs (n=1088) found that while silymarin showed a trend toward reduced liver-related mortality in liver disease trials, the results did not reach statistical significance when all trials were pooled, and the overall quality of evidence was assessed as low. The reviewers noted that positive results were associated with higher silymarin doses and alcoholic liver disease specifically.
[7, 8, 18]Toxic liver damage (supportive / adjunctive treatment)
Commission E approved indication. Silymarin protects hepatocytes from toxic insults by stabilizing cell membranes and enhancing detoxification capacity. Intravenous silibinin (Legalon SIL) is used in European hospitals as a specific antidote for Amanita phalloides (death cap) mushroom poisoning, where it blocks amatoxin uptake by hepatocytes via competitive inhibition of OATP1B3 transport proteins. A retrospective multicenter study by Mengs et al. (2012) reported that IV silibinin reduced mortality from Amanita poisoning to approximately 5-10% compared to historical mortality rates of 20-30% without specific antidotal therapy. Oral silymarin is also studied as supportive treatment for drug-induced liver injury (DILI).
[1, 2, 15]Non-alcoholic fatty liver disease (NAFLD / MASLD)
Growing clinical evidence supports silymarin for NAFLD. Zhong et al. (2017) meta-analysis of 8 RCTs (n=587) found silymarin significantly reduced AST and ALT levels in NAFLD patients. Solhi et al. (2014) RCT found silymarin (140 mg TID) significantly improved hepatic enzymes and ultrasound findings compared to placebo in NAFLD patients over 8 weeks. Mechanisms include reduction of hepatic lipid peroxidation, improvement of insulin sensitivity, and anti-inflammatory effects relevant to steatohepatitis progression.
[12, 13, 20]Hepatitis C (adjunctive support)
The SyNCH trial (Fried et al. 2012), a large, rigorous NCCIH-funded RCT (n=154), found that oral silymarin (420 mg or 700 mg TID for 24 weeks) did not significantly reduce serum ALT levels compared to placebo in patients with chronic hepatitis C who had failed interferon-based therapy. However, IV silibinin has shown antiviral activity against HCV in pilot studies. Silymarin may provide hepatoprotective benefit independent of direct antiviral effects, but oral silymarin alone is not considered an effective antiviral for HCV.
[9, 20]Digestive System
Dyspeptic complaints
Commission E approved indication for dyspeptic complaints. The bitter taste and cholagogue action of milk thistle stimulate digestive secretions (gastric acid, bile, pancreatic enzymes) and improve fat digestion. Indicated for upper GI symptoms associated with hepatobiliary dysfunction including bloating, flatulence, loss of appetite, and post-prandial discomfort, particularly when related to impaired bile flow.
[1, 2, 6]Gallbladder dysfunction and biliary insufficiency
Traditional use as a cholagogue to promote bile flow and support gallbladder function. The choleretic action of silymarin may help prevent cholesterol-supersaturated bile and support healthy bile composition. Used in European phytotherapy for functional biliary complaints. Limited direct clinical trial evidence for this specific indication.
[5, 6]Endocrine System
Type 2 diabetes mellitus (adjunctive glycemic support)
Huseini et al. (2006) double-blind, placebo-controlled trial in 51 type 2 diabetic patients found that silymarin (200 mg TID) for 4 months significantly reduced HbA1c (from 7.8% to 6.8%), fasting blood glucose, total cholesterol, LDL, and triglycerides compared to placebo. A subsequent trial (Hussain 2007) reported similar glycemic benefits. Mechanisms include improvement of insulin sensitivity, reduction of hepatic glucose output, antioxidant protection of pancreatic beta cells, and anti-inflammatory effects. Silymarin does not replace diabetic medications but may provide adjunctive metabolic support.
[10, 21]Reproductive System
Insufficient breast milk production (galactagogue)
Traditional use as a galactagogue dating back centuries, referenced in European herbalism. Di Pierro et al. (2008) RCT found micronized silymarin (420 mg/day) significantly increased milk production in lactating women compared to placebo over 63 days. The mechanism is not well characterized. Evidence is limited to one small trial and traditional use. Use as a galactagogue should be under professional guidance.
[6, 11]Skin / Integumentary
Skin conditions associated with hepatic dysfunction
In traditional Western herbalism, milk thistle is used for skin conditions believed to stem from impaired liver detoxification and clearance, including acne, eczema, and psoriasis with a hepatic component. The rationale is that supporting liver function improves the body's ability to process and eliminate metabolic waste products that may contribute to skin inflammation. Limited direct clinical evidence for dermatological outcomes.
[5, 6]Urinary System
Nephroprotection (adjunctive, preliminary)
Preclinical and limited clinical evidence suggests silymarin may protect renal tissue from drug-induced and oxidative nephrotoxicity. Silymarin has shown nephroprotective effects against cisplatin-, gentamicin-, and acetaminophen-induced renal injury in animal models. A pilot clinical study found silymarin reduced markers of kidney damage in patients receiving cisplatin chemotherapy. These findings are preliminary and require larger confirmatory trials.
[19, 20]Energetics
Temperature
cool
Moisture
dry
Taste
Tissue States
hot/excitation, damp/stagnation
Milk thistle seed is classified as cool and dry in Western herbal energetics. Its cooling nature aligns with its application for 'hot' liver conditions involving inflammation, congestion, and oxidative damage. The drying quality reflects its ability to resolve hepatic congestion and 'damp stagnation' in the hepatobiliary system, promoting bile flow and metabolic clearance. The dominant bitter taste indicates tropism for the liver and digestive system. In traditional energetic assessment, milk thistle is specific for the 'overheated, congested liver' pattern characterized by irritability, skin eruptions, digestive sluggishness, and signs of hepatobiliary stagnation. The Eclectic physicians classified Carduus marianus as a cooling bitter with specific liver affinity. CAVEAT: Herbal energetics are interpretive frameworks within Western herbalism, not standardized across all practitioners.
Traditional Uses
Ancient Greek and Roman medicine
- Dioscorides (1st century CE) described the seeds of 'Sillybos' for snakebite
- Pliny the Elder (Natural History, 1st century CE) recommended the juice of the plant mixed with honey for carrying off bile
- Theophrastus referenced related thistles in his botanical works
- Used as a liver and biliary remedy in Graeco-Roman medicine
"Pliny the Elder wrote in the Natural History that the juice of the plant mixed with honey was 'excellent for carrying off bile.' Dioscorides described the seeds as a remedy for venomous bites. The use of thistles for liver complaints appears across multiple ancient Mediterranean medical traditions."
Medieval European and monastic medicine
- Used by Hildegard von Bingen and other monastic herbalists for liver complaints
- The white veining of the leaves was associated with the Virgin Mary's milk (Doctrine of Signatures), reinforcing its use as a galactagogue
- Featured in numerous medieval herbals as 'Carduus Mariae'
- Employed for melancholy and conditions attributed to 'black bile' (hepatic-humoral theory)
"The Christian legend holds that the white marbling on the leaves was caused by drops of the Virgin Mary's milk falling on the plant, hence 'Marian thistle' and 'Lady's thistle.' This association linked the plant both to lactation support and to the sacred, elevating its status in monastic medicine. Medieval herbalists used it as a specific remedy for liver diseases and to counteract poisoning."
[16]
Renaissance and early modern European herbalism
- Culpeper (17th century) recommended milk thistle for obstructions of the liver and spleen
- Gerard's Herbal (1597) described its use as a liver remedy and for removing obstructions
- Used as a spring tonic and liver cleanser throughout rural Europe
- Young leaves and stems eaten as a vegetable (similar to artichoke) after removing spines
"Nicholas Culpeper wrote that milk thistle 'is the best remedy that grows against all melancholy diseases' and recommended it to 'open the obstructions of the liver and spleen, and thereby is good against the jaundice.' Gerard noted the peeled and soaked roots were 'eaten with oil and vinegar' and that the plant was 'good to expel melancholy.'"
Eclectic medicine (19th-early 20th century United States)
- Adopted by Eclectic physicians as a liver and spleen remedy
- Used for portal congestion, hepatic torpor, and splenomegaly
- Indicated for varicose veins and hemorrhoids attributed to portal hypertension
- Employed for menstrual irregularity associated with hepatic congestion
- Included in the Eclectic Materia Medica as Carduus marianus
"The Eclectic physicians valued Carduus marianus as a specific remedy for liver congestion and portal circulation disorders. Felter and Lloyd's King's American Dispensatory described it as useful for 'hepatic congestion with associated splenic enlargement and portal engorgement.' The Eclectics employed the tincture of the seeds for a range of hepatobiliary and digestive complaints."
European folk medicine and food
- Young leaves eaten as salad greens (after removing spines) throughout the Mediterranean
- Flower receptacles eaten like artichoke hearts
- Roasted seeds used as a coffee substitute in times of scarcity
- Roots boiled and eaten as a root vegetable
- Seeds used as a galactagogue for nursing mothers
- Tea of ground seeds for liver complaints, jaundice, and gallstones
"Milk thistle has a long history of culinary and medicinal use in Mediterranean folk culture. Nearly all parts of the plant have been consumed as food: young leaves as salad, flower receptacles like artichokes, roots as boiled vegetables, and roasted seeds as a coffee substitute. Its medicinal reputation has consistently centered on the liver throughout its folk medical history."
[16]
Modern Research
Silymarin for chronic liver disease: Cochrane systematic review
Cochrane systematic review and meta-analysis of 18 randomized clinical trials (n=1088) evaluating milk thistle (Silybum marianum) and silymarin preparations for treatment of alcoholic and/or hepatitis B or C liver diseases.
Findings: Silymarin versus placebo or no intervention showed no significant effect on all-cause mortality (RR 0.78, 95% CI 0.53-1.15), liver-related mortality (RR 0.54, 95% CI 0.26-1.11), or liver histology. However, there was a non-significant trend favoring silymarin for liver-related mortality. Subgroup analysis suggested potential benefit in alcoholic liver disease and in trials using higher-quality silymarin preparations. The authors noted that the overall quality of included trials was low, with high risk of systematic bias and random error.
Limitations: High heterogeneity across trials in terms of silymarin preparation, dose, duration, and patient population. Most included trials had methodological limitations (unclear randomization, inadequate blinding, small sample sizes). The reviewers emphasized the need for large, well-designed trials with standardized preparations. The review included studies from 1977-2005 and may not reflect more recent formulation advances (phytosomes).
[8]
Silymarin in alcoholic cirrhosis: survival benefit (landmark trial)
Double-blind, placebo-controlled randomized trial evaluating silymarin (140 mg TID, standardized to 70-80% silymarin) versus placebo in 170 patients with histologically proven liver cirrhosis (87 alcoholic, 83 non-alcoholic) over a mean follow-up of 41 months.
Findings: The 4-year survival rate was significantly higher in the silymarin group (58% +/- 9%) compared to placebo (39% +/- 9%) (P = 0.036). The survival benefit was most pronounced in the alcoholic cirrhosis subgroup (silymarin: 66% vs placebo: 37%) and in patients with Child-Pugh class A (early) cirrhosis. There were no significant adverse effects. This is considered the most influential positive trial for silymarin in liver disease.
Limitations: Single-center study (Vienna). Patient population predominantly alcoholic cirrhosis in Austria. Drop-out rate was notable. Adherence monitoring limited. The study has not been fully replicated in a comparably sized independent trial, though the SyNCH trial addressed a different population (HCV).
[7]
Comprehensive review of silymarin's hepatoprotective mechanisms
Narrative review synthesizing the molecular mechanisms of silymarin/silibinin hepatoprotection, covering antioxidant, anti-inflammatory, immunomodulatory, anti-fibrotic, and regenerative activities, along with clinical applications.
Findings: Identified four primary hepatoprotective mechanisms: (1) antioxidant activity via free radical scavenging, lipid peroxidation inhibition, and GSH maintenance; (2) cell membrane stabilization; (3) stimulation of hepatocyte regeneration through RNA polymerase I activation; (4) anti-fibrotic effects via inhibition of hepatic stellate cell activation. Additionally reviewed emerging evidence for anti-cancer (prostate, breast, colon), hypoglycemic, cardioprotective, and neuroprotective activities. Emphasized the bioavailability limitation of oral silymarin and the improved pharmacokinetics of phospholipid complexes.
Limitations: Narrative review; no systematic methodology. Extrapolation from preclinical findings to clinical benefit requires caution. Many mechanistic studies are in vitro or animal models.
[19]
Systematic review of silymarin for liver disease treatment
Comprehensive review of clinical and pharmacological data on silymarin preparations for the treatment of liver diseases, including assessment of quality of evidence and practical therapeutic recommendations.
Findings: Confirmed hepatoprotective mechanisms of silymarin (antioxidant, membrane-stabilizing, regenerative). Reviewed clinical evidence supporting use in alcoholic liver disease, drug-induced hepatotoxicity, and mushroom poisoning. Recommended standardized silymarin preparations (equivalent to 200-400 mg silymarin daily) as adjunctive treatment in chronic liver disease. Highlighted the role of IV silibinin for Amanita poisoning. Noted that clinical response depends on adequate dosing, standardized preparation quality, and duration of treatment.
Limitations: Variable quality of clinical trials reviewed. Heterogeneity of silymarin preparations across studies complicates meta-analytic conclusions.
[18]
Molecular mechanisms of silymarin beyond hepatoprotection
Review of silymarin's pharmacological activities beyond traditional liver protection, including anti-cancer, anti-diabetic, cardioprotective, and neuroprotective effects, with emphasis on molecular targets and signaling pathways.
Findings: Identified silymarin/silibinin activity on multiple molecular targets: NF-kB suppression (anti-inflammatory), STAT3 inhibition (anti-cancer), AMPK activation (metabolic), Nrf2 induction (antioxidant gene expression), mTOR modulation, and epigenetic effects (DNMT inhibition, histone modification). Reviewed preclinical evidence for anti-cancer activity in prostate, skin, breast, colorectal, and lung cancer models. Noted that silibinin is in Phase I/II clinical trials for prostate cancer. Highlighted the anti-diabetic potential through improved insulin sensitivity and reduced hepatic gluconeogenesis.
Limitations: Most evidence for non-hepatic indications is preclinical (in vitro and animal models). Clinical translation for cancer and metabolic indications is still in early stages. Bioavailability remains a challenge for achieving effective tissue concentrations outside the liver.
[20]
Silymarin for non-alcoholic fatty liver disease (NAFLD): meta-analysis
Meta-analysis of 8 randomized controlled trials (n=587) evaluating the efficacy of silymarin for treatment of NAFLD/NASH, assessing effects on liver enzymes, ultrasound findings, and metabolic parameters.
Findings: Silymarin significantly reduced AST (SMD -0.81, 95% CI -1.35 to -0.27) and ALT (SMD -0.55, 95% CI -0.92 to -0.19) levels compared to controls. Improvements in ultrasound findings and some metabolic parameters (fasting glucose, insulin resistance indices) were also observed in individual trials. The pooled data suggest silymarin has a beneficial effect on biochemical markers of liver injury in NAFLD.
Limitations: High heterogeneity among included trials (different silymarin preparations, doses, durations, and comparison groups). Most trials were small. Publication bias possible. Long-term histological outcomes were not assessed. Does not prove clinical endpoint improvement (fibrosis regression, prevention of cirrhosis).
[13]
Oral silymarin for chronic hepatitis C: the SyNCH trial
NCCIH-funded, multicenter, double-blind, placebo-controlled RCT evaluating oral silymarin (420 mg or 700 mg three times daily) for 24 weeks in 154 patients with chronic hepatitis C who had failed prior interferon-based therapy. Primary endpoint: decline in serum ALT to below 45 U/L.
Findings: Neither dose of oral silymarin produced a significantly greater decline in serum ALT compared to placebo. Serum ALT reached the normal range in 6/56 (11%) in the silymarin 420 mg group, 5/51 (10%) in the 700 mg group, and 4/47 (9%) in placebo. No significant changes in HCV RNA levels were observed. Silymarin was well tolerated at both doses.
Limitations: Population was specifically HCV-positive patients who had failed interferon therapy (refractory population). Oral bioavailability of silymarin may have been insufficient to achieve effective hepatic concentrations. IV silibinin has shown antiviral HCV effects in other studies, suggesting the oral route may be the limiting factor. Does not negate hepatoprotective benefit independent of antiviral activity.
[9]
Silymarin for glycemic control in type 2 diabetes
Double-blind, placebo-controlled trial in 51 type 2 diabetic patients evaluating silymarin (200 mg TID) as an add-on to conventional antidiabetic therapy for 4 months.
Findings: Silymarin significantly reduced HbA1c (from 7.8% to 6.8% vs 8.0% to 7.9% with placebo, P < 0.001), fasting blood glucose, total cholesterol, LDL cholesterol, and triglycerides compared to placebo. Hepatic enzymes (AST, ALT) also improved. No significant adverse effects were reported.
Limitations: Small sample size (n=51). Single-center. Short duration (4 months). Iranian population; results may not generalize. Add-on therapy design means effects of silymarin cannot be fully separated from background treatment. Replication in larger, multi-center studies needed.
[10]
Micronized silymarin as a galactagogue
Randomized, double-blind, placebo-controlled trial evaluating micronized silymarin (BIO-C, 420 mg/day) versus placebo for 63 days in healthy lactating women to assess effects on breast milk production.
Findings: Daily milk production increased by 85.9% in the silymarin group compared to 32.1% in the placebo group (P < 0.01). No adverse effects were reported in mothers or infants. The authors attributed the enhanced bioavailability of the micronized formulation as a factor in the positive outcome.
Limitations: Small sample size. Single study; not yet replicated. Mechanism of galactagogue action not established. Micronized formulation may not be equivalent to standard silymarin preparations. Duration limited to 63 days.
[11]
Preparations & Dosage
Standardized Extract
Strength: DER approximately 36-44:1 (concentrated extract). Standardized to contain 70-80% silymarin as silibinin (HPLC). Typical capsule: 140-175 mg silymarin per capsule.
Capsules or tablets containing silymarin extract standardized to 70-80% total silymarin (calculated as silibinin by HPLC). This is the most extensively studied and clinically validated preparation form. Standard commercial products include Legalon, Thisilyn, and generic silymarin extracts. Phospholipid complexes (phytosomes, e.g., Siliphos / silybin-phosphatidylcholine) offer 3-5x improved bioavailability.
420-600 mg silymarin daily (equivalent to 200-300 mg silibinin), divided into 2-3 doses. Typical: 140-200 mg silymarin TID. For phospholipid complex (phytosome): 120-240 mg silybin-phytosome BID-TID.
2-3 times daily with meals (food improves absorption of lipophilic silymarin)
Minimum 8-12 weeks for chronic liver conditions. May be used long-term (clinical trials used up to 41 months). Reassess periodically. For acute toxic exposure, higher doses for shorter periods under medical supervision.
Not well-established for children. Limited data. Use only under professional supervision.
The standardized extract is the preparation used in virtually all clinical trials and is endorsed by Commission E, WHO, ESCOP, and EMA. Bioavailability of standard silymarin extract is limited (20-50% oral absorption) due to poor water solubility. Phospholipid complexes (phytosomes) significantly improve bioavailability and should be considered for clinical applications requiring higher systemic levels. Take with meals for improved absorption. European pharmaceutical-grade products (e.g., Legalon 140) are the most rigorously quality-controlled.
capsule-powder
Strength: Crude dried seed powder, typically 500 mg per capsule. Silymarin content approximately 1.5-3% of seed weight (varies by batch).
Dried, ground milk thistle seeds encapsulated as whole seed powder. Less concentrated than standardized extract but retains the full spectrum of seed constituents including fixed oil, protein, betaine, and flavonolignans.
2-5 g of ground seed daily (typically 4-6 capsules of 500 mg), divided into 2-3 doses. This provides approximately 30-150 mg silymarin daily depending on seed quality.
2-3 times daily with meals
May be used long-term as a liver tonic. Reassess after 8-12 weeks for specific conditions.
Not recommended for children in capsule form
Ground seed preparations deliver less silymarin per dose than standardized extracts, but some herbalists prefer them as a gentler, whole-plant preparation for long-term liver support and general tonic use. The fixed oil content may improve silymarin solubility. Seeds must be ground or crushed before ingestion, as whole seeds pass through the GI tract largely undigested due to the hard seed coat. Grinding immediately before use or purchasing pre-ground capsules is recommended.
Tincture
Strength: 1:3 to 1:5, 60-70% ethanol (dried seed)
Hydroethanolic extraction of crushed/ground dried milk thistle seeds. Standard ratio 1:3 to 1:5 in 60-70% ethanol. Higher alcohol content is needed due to the lipophilic nature of silymarin flavonolignans. Macerate crushed seeds for 4-6 weeks with regular agitation, then press and filter.
3-5 mL (60-100 drops) three times daily
Three times daily, taken before or with meals
May be used for extended periods. Reassess therapeutic need periodically.
Not recommended for children in tincture form due to alcohol content and limited pediatric data
The tincture requires high-percentage ethanol (60-70%) to adequately extract the lipophilic silymarin flavonolignans. Lower alcohol percentages will yield preparations with significantly reduced silymarin content. Some practitioners consider tinctures less effective than standardized extracts for serious liver conditions because silymarin extraction efficiency in tinctures is variable. The tincture form may be preferred by herbalists for its full-spectrum extraction profile and ease of combining with other hepatic herbs (e.g., dandelion root, burdock, artichoke leaf).
Decoction
Strength: 3.5-5 g crushed seeds per 200-250 mL water
Simmer 3.5-5 g of freshly crushed or coarsely ground milk thistle seeds in 200-250 mL water for 15-20 minutes. Strain and drink. The seeds must be thoroughly crushed or ground before boiling to release silymarin from the hard seed coat.
One cup (200-250 mL) three times daily, 30 minutes before meals
Three times daily
May be used for extended periods for general liver support
Not well established
Water extraction of silymarin is inherently limited due to the poor water solubility of the flavonolignans. A decoction will extract some silymarin (especially when seed coat is thoroughly disrupted) along with water-soluble constituents (betaine, some flavonoids, mucilage) but delivers substantially less silymarin per dose than a standardized extract or high-alcohol tincture. This preparation is used in traditional folk medicine and may be appropriate for mild, general liver tonic purposes. Not recommended as a primary preparation for serious liver conditions where clinical evidence supports standardized extracts.
Glycerite
Strength: 1:5, 70% glycerin / 30% water
Extraction of crushed dried seeds in vegetable glycerin and water (70:30 glycerin to water ratio). Macerate for 6-8 weeks with daily agitation. Higher glycerin ratio helps solubilize some of the lipophilic compounds. Press and filter.
3-5 mL three times daily
Three times daily
May be used for extended periods
Not well established; use only under professional guidance
Alcohol-free preparation for those avoiding ethanol. Glycerites extract silymarin less efficiently than high-percentage ethanol tinctures. Suitable for mild liver support or as part of combination formulas. The sweet taste of glycerin makes it more palatable. Not recommended as a primary preparation for serious liver conditions.
[6]
Infusion (Tea)
Strength: 3-3.5 g crushed seeds per 200-250 mL water
Pour 200-250 mL of boiling water over 3-3.5 g of freshly crushed milk thistle seeds. Cover and steep for 10-15 minutes. Strain before drinking.
One cup 3-4 times daily, 30 minutes before meals
3-4 times daily
May be used long-term as a gentle liver tonic
Not well established
An infusion extracts even less silymarin than a decoction due to the shorter contact time and lack of prolonged heating. Similar limitations to decoction regarding silymarin bioavailability. Appropriate for mild, daily liver tonic use in traditional practice. The WHO monograph describes this preparation form. Seeds must be freshly crushed to disrupt the hard seed coat.
[2]
Safety & Interactions
Class 1
Can be safely consumed when used appropriately (AHPA Botanical Safety Handbook)
Contraindications
Allergic reactions to milk thistle are rare but documented. Patients with established allergies to ragweed, chrysanthemums, marigolds, daisies, or other Asteraceae plants may be at elevated risk for cross-reactivity. Reported reactions include urticaria, pruritus, and rare anaphylaxis. Discontinue use if any signs of allergic reaction occur.
Drug Interactions
| Drug / Class | Severity | Mechanism |
|---|---|---|
| CYP2C9 substrates (warfarin, phenytoin, diclofenac, losartan) (CYP2C9 substrates) | theoretical | In vitro studies suggest silymarin may inhibit CYP2C9. However, clinical pharmacokinetic studies in humans have generally found no significant effect on CYP2C9-mediated drug metabolism at standard oral doses. A clinical study by Gurley et al. (2006) found no significant effect of milk thistle on CYP2C9 activity (midazolam, caffeine, chlorzoxazone, and debrisoquin probe substrates). |
| CYP3A4 substrates (cyclosporine, statins, calcium channel blockers, protease inhibitors) (CYP3A4 substrates) | theoretical | In vitro data suggest silymarin components may inhibit CYP3A4. However, the Gurley et al. (2006) human pharmacokinetic study found no clinically significant effect of milk thistle on CYP3A4 activity using midazolam as a probe substrate. A study by Rao et al. (2007) found no effect of silymarin on indinavir pharmacokinetics. The clinical relevance of in vitro CYP3A4 inhibition appears negligible at standard oral doses. |
| Metformin and other antidiabetic medications (Hypoglycemic agents) | minor | Silymarin has demonstrated modest hypoglycemic effects in clinical trials (Huseini et al. 2006). Additive blood glucose lowering is possible when combined with antidiabetic medications. |
| Sirolimus (Rapamycin) and related immunosuppressants (Immunosuppressants) | theoretical | In vitro and animal data suggest silymarin may affect P-glycoprotein (P-gp) and organic anion transporting polypeptides (OATPs), which are involved in the disposition of sirolimus and other immunosuppressants. A case report described elevated sirolimus levels in a renal transplant patient taking milk thistle. |
| Raloxifene, tamoxifen, and estrogen-containing medications (Hormonal agents) | theoretical | Silymarin has demonstrated weak estrogenic activity in some in vitro assays, binding to estrogen receptors. Theoretical concern for interaction with selective estrogen receptor modulators (SERMs) or estrogen-containing preparations. However, other studies suggest silymarin may have anti-estrogenic properties in certain tissues. |
Pregnancy & Lactation
Pregnancy
insufficient data
Lactation
likely safe
Pregnancy: There are no adequate human safety studies of silymarin during pregnancy. Animal reproductive toxicity studies have not shown teratogenic effects at typical doses. The EMA assessment report notes that use during pregnancy has not been established due to lack of adequate data. Given the absence of known toxicity and centuries of traditional food use of the plant, the risk is likely low, but standardized extracts at therapeutic doses should be used only if the potential benefit justifies the theoretical risk. Consult a healthcare provider. Lactation: Milk thistle has a long traditional history as a galactagogue. Di Pierro et al. (2008) used micronized silymarin in breastfeeding women with no adverse effects reported in mothers or infants. The LactMed database notes that milk thistle is generally considered compatible with breastfeeding. Moderate use is likely safe during lactation. Commission E does not list pregnancy or lactation as contraindications.
Adverse Effects
References
Monograph Sources
- [1] German Commission E (Bundesinstitut fur Arzneimittel und Medizinprodukte). Commission E Monograph: Cardui mariae fructus (Milk Thistle Fruit) -- Positive. Bundesanzeiger (Federal Gazette) (1986)
- [2] World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 2: Fructus Silybi Mariae. World Health Organization, Geneva (2002) : 300-316
- [3] Committee on Herbal Medicinal Products (HMPC), European Medicines Agency. European Union Herbal Monograph on Silybum marianum (L.) Gaertn., fructus. European Medicines Agency (2018)
- [4] ESCOP (European Scientific Cooperative on Phytotherapy). ESCOP Monographs: Silybi mariani fructus (Milk Thistle Fruit), 2nd Edition Supplement. Thieme, Stuttgart (2009)
- [5] Blumenthal M, Busse WR, Goldberg A, Gruenwald J, Hall T, Riggins CW, Rister RS (eds). The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. American Botanical Council, Austin, TX (1998) . ISBN: 978-0965555500
- [6] Hoffmann D. Medical Herbalism: The Science and Practice of Herbal Medicine. Healing Arts Press, Rochester, VT (2003) . ISBN: 978-0892817498
Clinical Studies
- [7] Ferenci P, Dragosics B, Dittrich H, Frank H, Benda L, Lochs H, Meryn S, Base W, Schneider B. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol (1989) ; 9 : 105-113 . DOI: 10.1016/0168-8278(89)90083-4 . PMID: 2687667
- [8] Rambaldi A, Jacobs BP, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. Cochrane Database Syst Rev (2007) ; 4 : CD003620 . DOI: 10.1002/14651858.CD003620.pub3 . PMID: 17943848
- [9] Fried MW, Navarro VJ, Afdhal N, Belle SH, Wahed AS, Hawke RL, Doo E, Meyers CM, Reddy KR; SyNCH Trial Group. Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial. JAMA (2012) ; 308 : 274-282 . DOI: 10.1001/jama.2012.8265 . PMID: 22797645
- [10] Huseini HF, Larijani B, Heshmat R, Fakhrzadeh H, Radjabipour B, Toliat T, Raza M. The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial. Phytother Res (2006) ; 20 : 1036-1039 . DOI: 10.1002/ptr.1988 . PMID: 17072885
- [11] Di Pierro F, Callegari A, Carotenuto D, Tapia MM. Clinical efficacy, safety and tolerability of BIO-C (micronized Silymarin) as a galactagogue. Acta Biomed (2008) ; 79 : 205-210 . PMID: 19260380
- [12] Solhi H, Ghahremani R, Kazemifar AM, Hoseini Yazdi Z. Silymarin in treatment of non-alcoholic steatohepatitis: A randomized clinical trial. Caspian J Intern Med (2014) ; 5 : 9-12 . PMID: 24490006
- [13] Zhong S, Fan Y, Yan Q, Fan X, Wu B, Han Y, Zhang Y, Chen Y, Zhang H, Niu J. The therapeutic effect of silymarin in the treatment of nonalcoholic fatty disease: A meta-analysis (PRISMA) of randomized control trials. Medicine (Baltimore) (2017) ; 96 : e9061 . DOI: 10.1097/MD.0000000000009061 . PMID: 29245314
- [14] Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Carrier J, Khan IA, Edwards DJ, Shah A. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther (2006) ; 79 : 428-439 . DOI: 10.1016/j.clpt.2006.01.009 . PMID: 16678546
- [15] Mengs U, Pohl RT, Mitchell T. Legalon SIL: the antidote of choice in patients with acute hepatotoxicity from amatoxin poisoning. Curr Pharm Biotechnol (2012) ; 13 : 1964-1970 . DOI: 10.2174/138920112802273353 . PMID: 22352731
Traditional Texts
- [16] Grieve M. A Modern Herbal: The Medicinal, Culinary, Cosmetic and Economic Properties, Cultivation and Folk-Lore of Herbs, Grasses, Fungi, Shrubs & Trees with Their Modern Scientific Uses. Jonathan Cape, London (1931)
- [17] Felter HW, Lloyd JU. King's American Dispensatory, 18th edition. Ohio Valley Company, Cincinnati (1898)
Pharmacopeias & Reviews
- [18] Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs (2001) ; 61 : 2035-2063 . DOI: 10.2165/00003495-200161140-00003 . PMID: 11735632
- [19] Abenavoli L, Capasso R, Milic N, Capasso F. Milk thistle in liver diseases: past, present, future. Phytother Res (2010) ; 24 : 1423-1432 . DOI: 10.1002/ptr.3207 . PMID: 21466434
- [20] Polyak SJ, Ferenci P, Pawlotsky JM. Hepatoprotective and antiviral functions of silymarin components in hepatitis C virus infection. Hepatology (2013) ; 57 : 1262-1271 . DOI: 10.1002/hep.26179 . PMID: 23213025
- [21] Voroneanu L, Nistor I, Dumea R, Apetrii M, Covic A. Silymarin in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Diabetes Res (2016) ; 2016 : 5147468 . DOI: 10.1155/2016/5147468 . PMID: 27340676
- [22] Flora K, Hahn M, Rosen H, Benner K. Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol (1998) ; 93 : 139-143 . DOI: 10.1111/j.1572-0241.1998.00139.x . PMID: 9507170
Last updated: 2026-02-26 | Status: review